Recent studies showed that Crizotinib is also active against anaplastic lymphoma kinase (ALK) [24, 25] and has been approved for the treatment of locally advanced or metastatic non small cell lung cancer that is ALK-positive [26]. This evidence concerns the gene ALK and non-small cell lung carcinoma.